Your browser doesn't support javascript.
Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies.
Radhwi, Osman O; Jan, Hamza; Waheeb, Abdullah; Alamri, Sawsan S; Alahwal, Hatem M; Denetiu, Iuliana; Almanzlawey, Ashgan; Al-Marzouki, Adel F; Almohammadi, Abdullah T; Bahashwan, Salem M; Barefah, Ahmed S; Qari, Mohamad H; Abuzenadah, Adel M; Hashem, Anwar M.
  • Radhwi OO; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Jan H; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Waheeb A; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Alamri SS; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Alahwal HM; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Denetiu I; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Almanzlawey A; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Al-Marzouki AF; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Almohammadi AT; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Bahashwan SM; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Barefah AS; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Qari MH; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Abuzenadah AM; Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
  • Hashem AM; Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.
Vaccines (Basel) ; 10(2)2022 Jan 20.
Article in English | MEDLINE | ID: covidwho-1649502
ABSTRACT

INTRODUCTION:

Studies assessing immune responses following Pfizer-BioNTech BNT162b2 mRNA COVID-19 (Pfizer) and ChAdOx1 nCoV-19 AZD1222 (AstraZeneca) vaccines in patients with hemoglobinopathy are non-existent in the literature despite being thought at high risk of infection.

METHODS:

Prospectively, we collected serum from patients with hemoglobinopathies at least 14 days post vaccine and measured neutralizing antibodies (nAb) in addition to binding antibodies using in-house assays.

RESULTS:

All 66 participants mounted a significant binding antibody response (100%), but nAbs were detected in (56/66) post-vaccine with a rate of 84.5%. Age, gender, vaccine type, spleen status, hydroxyurea use, and hyperferritinemia did not affect the rate significantly. While 23/32 (71.8%) patients receiving only one dose of the vaccine were able to mount a positive response, 33/34 (97.05%) of those who had two doses of any vaccine type had a significant nAbs response. Patients who had anti-nucleocapsid (N), signifying asymptomatic infection in the past, were able to produce nAbs (31/31). No nAbs were detected in 10/35 (28.5%) patients with no anti-N antibodies.

CONCLUSION:

Our results provide supportive data when advising patients with hemoglobinopathy to receive COVID-19 vaccines and ensure booster doses are available for better immunity. Whenever available, measurement of nAb is recommended.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020151

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020151